

## #617P

<sup>1</sup>Urology, Osaka University Graduate School of Medicine; <sup>2</sup>Medical Oncology, National Cancer Center Hospital East; <sup>3</sup>Head and Neck Medical Oncology, National Cancer Center Hospital East; <sup>4</sup>Urology, Kyushu University Graduate School of Medical Science; <sup>5</sup>Renal and Genitourinary Surgery, Hokkaido University Graduate School of Medicine; <sup>6</sup>Urology, Keio University School of Medicine; <sup>7</sup>Uro-Oncology, International Medical Center, Saitama Medical University; <sup>8</sup>Translational Research Support Section, National Cancer Center Hospital East; <sup>9</sup>Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East

For the first time, we performed comprehensive genomic profiling of ctDNA in GU cancers. We further evaluate ctDNA profiling before and after starting cancer treatments and connect these data to clinical trials.

From North to South:

1. Hokkaido University Hospital
2. University of Tsukuba
3. National Cancer Center Hospital East
4. Chiba Cancer Center
5. Saitama Cancer Center
6. National Cancer Center Hospital
7. Keio University School of Medicine
8. Kyorin University Hospital
9. The Cancer Institute Hospital of JFRC
10. St. Marianna University School of Medicine
11. Kanagawa Cancer Center
12. Shizuoka Cancer Center
13. Kanazawa University
14. Aichi Cancer Center Hospital
15. Osaka University Graduate School of Medicine
16. Kindai University
17. Kansai Rosai Hospital
18. National Hospital Organization Shikoku Cancer Center
19. National Hospital Organization Kyushu Cancer Center
20. Kyushu University
21. National Hospital Organization Osaka National Hospital
22. Kagawa University
23. Saitama Medical University International Medical Center
24. Kobe City Medical Center General Hospital
25. Gifu University Hospital
26. Osaka Medical College Hospital
27. Shimane Prefectural Central Hospital
28. Kansai Medical University Hospital
29. Kyoto Katsura Hospital
30. Osaka International Cancer Institute
31. Osaka General Medical Center

Cancer Type	Sequencing success rate (%)
Non-GU	93.1%
GU	86.7%
Prostate	87.3%
Urothelial	89.0%
Renal	82.8%

$p=0.0028$

- No potential conflicts were disclosed.